Expression of Matrix-Metalloproteases in the Fluid of Chronic Diabetic Foot Wounds Treated with a Protease Absorbent Dressing

Abstract

It is well known, that wound healing in diabetes is impaired. Persistently high levels of matrix-metalloproteases (MMPs) contribute to wound persistence. The topical use of protease-inhibitors might beneficially affect wound healing.

Research design and methods: 19 patients with chronic diabetic foot lesions (Wagner/Armstrong 2A) were studied. 6 patients received “good standard wound care”, 13 patients were treated with a protease-inhibitor-modulating-matrix (ORC/collagen matrix) that was changed daily. At day 1 and 5 biopsies were taken from the wounds; wound fluids were collected daily. Biopsies were analysed using quantitative real-time-PCR and all samples were analysed using ELISA and zymography for MMPs, TIMPs, IL 1-β and TNFα levels.

Results: No differences in mRNA-expression of MMPs, TNFα and for MMP levels in wound tissue were detected between both groups or between the 2 sampling time points. MMP-2 active was significantly reduced in wound fluids of ORC/collagen treated lesions (p=0.043) after 5 days. MMP-2 pro was also reduced by about 25% when compared to increasing levels in the control group (+27%). We observed a significant reduction of the wound area in the ORC/collagen group (p=0.003).

Conclusions: Local treatment with a protease-inhibitor has a beneficial effect on wound healing. In contrast to unchanged mRNA-levels and protein levels of MMPs there was a clear reduction of MMP-2-levels in wound fluids. Our data support the potential role of ORC/collagen as a wound dressing. Modulation of MMPs appears to be beneficial in the treatment of chronic diabetic wounds.

Key words

diabetic foot syndrome - matrix-metalloproteases - protease absorbent dressing

References

• 1 Boyko EJ, Ahroni JH, Smith DG. et al . Increased mortality associated with diabetic foot ulcers.  Diabet Med. 1996;  13 967-972
• 2 Frykberg RG. Diabetic foot ulcerations: management and adjunctive therapy.  Clin Podiatr Med Surg. 2003;  20 709-728
• 3 Saar WE, Lee TH, Berlet GC. The economic burden of diabetic foot and ankle disorders.  Foot Ankle Int. 2005;  26 27-31
• 4 Ramsey SD, Newton K, Blough D. et al . Incidence, outcomes, and cost of foot ulcers in patients with diabetes.  Diabetes Care. 2001;  22 (3) 382-387
• 5 Lobmann R, Mueller E, Kersken J. et al . The diabetic foot in Germany: Analysis of Quality in specialised diabetic wound care centers.  The Diabetic Foot Journal. 2007;  10 68-72
• 6 Heller G, Gunster C, Schellschmidt H. How frequent are diabetes-related amputations of the lower limbs in Germany? An analysis on the basis of routine data.  Dtsch Med Wochenschr. 2004;  129 429-433
• 7 Trautner C, Haastert B, Giani G. et al . Amputations and diabetes: a case-control study.  Diabet Med. 2002;  19 35-40
• 8 Lobmann R, Ambrosch A, Schultz G. et al . Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients.  Diabetologia. 2002;  45 1011-1016
• 9 Lobmann R, Schultz G, Lehnert H. Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications.  Diabetes Care. 2005;  28 461-471
• 10 Mast BA, Schultz GS. Interactions of cytokines, growth factors and proteases in acute and chronic wounds.  Wound Repair Regen. 1996;  4 420-441
• 11 Trengove NJ, Stacey MC, MacAuley S. et al . Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors.  Wound Repair Regen. 1999;  7 442-452
• 12 Yager DR, Nwomeh BC. The proteolytic environment of chronic wounds.  Wound Repair Regen. 1999;  7 433-441
• 13 Claxton MJ, Armstrong DG, Boulton AJ. Healing the diabetic wound and keeping it healed: modalities for the early 21^st century.  Curr Diab Rep. 2002;  2 510-518
• 14 Nwomeh BC, Yager DR, Cohen IK. Physiology of the chronic wound.  Clin Plast Surg. 1998;  25 341-356
• 15 Falanga V. Wound healing and its impairment in the diabetic foot.  Lancet. 2005;  366 1736-1743
• 16 Medina A, Scott PG, Ghahary A. et al . Pathophysiology of chronic nonhealing wounds.  J Burn Care Rehabil. 2005;  26 306-319
• 17 Tomic-Canic M, Brem H. Gene array technology and pathogenesis of chronic wounds.  Am J Surg. 2004;  188 67-72
• 18 Singer AJ, Clark RA. Cutaneous wound healing.  N Engl J Med. 1999;  341 738-746
• 19 Doxey DL, Ng MC, Dill RE. et al . Platelet-derived growth factor levels in wounds of diabetic rats.  Life Sci. 1995;  57 1111-1123
• 20 Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers.  Wound Repair Regen. 2000;  8 13-25
• 21 Morris EJ, Dowlen S, Cullen B. Early clinical experience with topical collagen in vascular wound care.  J Wound Ostomy Continence Nurs. 1994;  21 247-250
• 22 Cullen B, Smith R, McCulloch E. et al . Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers.  Wound Repair Regen. 2002;  10 16-25
• 23 Cullen B, Watt PW, Lundqvist C. et al . The role of oxidised regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action.  Int J Biochem Cell Biol. 2002;  34 1544-1556
• 24 Ghatnekar O, Willis M, Persson U. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in 4 European countries.  J Wound Care. 2002;  11 70-74
• 25 Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs. standard treatment in the management of diabetic foot ulcers.  Arch Surg. 2002;  137 822-827
• 26 World Medical Association. . Declaration of Helsinki: ethical principles for medical research involving human subjects.  JAMA. 2000;  284 3043-3045
• 27 Shigeyama Y, Pap T, Kunzler P. et al . Expression of osteoclast differentiation factor in rheumatoid arthritis.  Arthritis Rheum. 2000;  43 2523-2530
• 28 Petri JB, König S, Haupt B. et al . Molecular analysis of different phases in human wound healing.  Experimental Dermatology. 1997;  6 133-139
• 29 Tarnuzzer RW, Schultz GS. Biochemical analysis of acute and chronic wound environments.  Wound Repair Regen. 1996;  4 321-325
• 30 Armstrong DG, Jude EB. The role of matrix metalloproteinases in wound healing.  J Am Podiatr Med Assoc. 2002;  92 12-18
• 31 Omugha N, Jones AM. The management of hard-to-heal necrobiosis with PROMOGRAN.  Br J Nurs. 2003;  12 S14-S20
• 32 Ghatnekar O, Willis M, Persson U. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in 4 European countries.  J Wound Care. 2002;  11 70-74
• 33 Vin F, Teot L, Meaume S. The healing properties of promogran in venous leg ulcers.  J Wound Care. 2002;  11 335-341
• 34 Hart J, Silcock D, Gunnigle S. et al . The role of oxidised regenerated cellulose/collagen in wound repair: effects in vitro on fibroblast biology and in vivo in a model of compromised healing.  Int J Biochem Cell Biol. 2002;  34 1557-1570
• 35 Lobmann R, Zemlin C, Motzkau M. et al . Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing.  J Diabetes Complications. 2006;  20 329-335
• 36 Liu Y, Min D, Bolton T. et al . Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers.  Diabetes Care. 2009;  32 (1) 117-119
• 37 Brandner JM, Zacheja S, Houdek P. et al . Expression of matrix metalloproteinases, cytokines, and connexins in diabetic and nondiabetic human keratinocytes before and after transplantation into an ex vivo wound-healing model.  Diabetes Care. 2008;  31 (1) 114-120

Correspondence